Wednesday, July 8, 2026

Patent intelligence · US

US 11884656

Pyrrole derivatives as PLK1 inhibitors

granted A61PA61P35/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 18
Applicant portfolio 95
Patent details — US 11884656

Quick answer

US 11884656 (Pyrrole derivatives as PLK1 inhibitors) is held by SENTINEL ONCOLOGY LIMITED. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
20
CPC classes
A61P, A61P35/00

More from SENTINEL ONCOLOGY LIMITED

Related pharmaceutical patents in our USPTO index.

  1. US 12419895

    Methods for treating subjects with Prader-Willi syndrome

    ESSENTIALIS, INC. · Expires Sep 18, 2045

    granted
  2. US 12350258

    Compositions and methods for treatment of skin-related diseases and promoting dermatological health

    Script Essentials, LLC · Expires Jul 3, 2045

    granted
  3. US 12343348

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Jun 26, 2045

    granted
  4. US 12343381

    Dosage regimen for pegylated interferon

    PHARMAESSENTIA CORPORATION · Expires Jun 26, 2045

    granted
  5. US 12178823

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Dec 26, 2044

    granted
  6. US 12109216

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Expires Oct 3, 2044

    granted
  7. US 12005081

    Chimeric receptors and methods of use thereof

    Senti Biosciences, Inc. · Expires Jun 6, 2044

    granted

Frequently asked questions

What is US patent 11884656?

US 11884656 (Pyrrole derivatives as PLK1 inhibitors) is held by SENTINEL ONCOLOGY LIMITED. Status: granted. Granted Jan 30, 2024. Expires Jan 25, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11884656?

SENTINEL ONCOLOGY LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 95 pharmaceutical patents for this assignee.

When does US 11884656 expire?

Our index shows an expiration date of Jan 25, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.